Core Insights - Shenzhen has established itself as a leading area for the biopharmaceutical industry, particularly in cell and gene therapy (CGT), supported by the introduction of the first national legislation for the sector, the "Shenzhen Special Economic Zone Cell and Gene Industry Promotion Regulations" [1] - The CGT industry in Shenzhen is projected to generate over 8.5 billion yuan in total revenue by 2024, with nearly 200 companies in the industry chain and 17 CGT products currently in clinical trials [1] - The integration of national platforms and local funding has created a robust ecosystem that accelerates the clinical transformation of CGT products [3] Group 1 - Shenzhen's policy framework includes a comprehensive support system from basic research to industrial transformation, reinforced by the "20+8" industrial cluster policy [1] - The establishment of the cell and gene industry fund at the municipal level has contributed to a synergistic ecosystem characterized by "policy guidance + platform support + capital empowerment" [3] - The "818 Order" from the State Council provides a clear compliance pathway for clinical research and application, enhancing the stability of policy expectations for technological innovation and industrial transformation [3] Group 2 - The director of the National Engineering Research Center for Key Common Technologies in the Cell Industry suggests leveraging stem cell therapies as clinical engines while developing digitalized production lines and integrated quality monitoring platforms [5] - This proposed model aims to create a closed-loop industrial ecosystem that can be replicated in other biomedical technology fields, attracting more companies to the industry chain [5] - The complete cycle of "clinical transformation (technology) → standardized production (intelligent manufacturing) → compliance regulation (quality inspection) → data feedback optimizing technology/manufacturing" is emphasized as a pathway to build a vibrant biomedical technology industry cluster [5]